COLORADO SPRINGS, Colo.,
Oct. 17, 2013 /PRNewswire/ -- Endocan
Corporation (FKA The X-Change Corporation) (NASDAQ OTC: XCHC), a
U.S. Company specializing in cannabinoid formulation-based health
and wellness solutions, is pleased to announce the Endocan™
website, www.endocan.com as well as the Company's social media
sites including the Facebook page and Twitter account are updated,
fully functional, and released today.
The website promotes the Endocan™ brand and will serve as a
platform for new product releases, designed for patients
internationally. Of course, the website includes all the
regular Endocan™ Corporate information including management
biographies, contact information and investor
relations. Endocan Corporation is creating an enhanced
international brand and image blending scientific expertise and
patient oriented approach to enhance patient health with its
proprietary cannabis and cannabinoid based formulations.
As well, the website has a pre-registration for its Patient
Resource Center that is being developed to provide education and
information on cannabis based medicine. The Patient Resource
Center is focused on noting patients' feedback to improve future
product development and new product release systems. The
Center will help patients to share personal information,
experiences, and also will provide the opportunity to participate
on a voluntary basis in the Center's confidential internal tracking
and anonymized data sharing systems.
Robert Kane, CFO & SVP
Business Development, Endocan Corporation, stated, "We aim to make
our Endocan™ website an incredible resource for all those involved
with us and the industry on many levels. We are proud to take
this important step in realizing our goal of creating a website
that accurately captures our vision, communicates our message, and
educates those who are looking for cannabis and cannabinoid
knowledge."
In the United States dispensary
owners across the United States
will be licensed to release the Company's brands and formulations
for retail distribution through licensing agreements utilizing the
Endocan™ brand name. In Canada,
the Company has an established network of professionals and
regulatory experts to bring its products to market for patient use.
Initially, the Company will be releasing its formulations through
several expert relationships across Canada. The Company has established two
subsidiaries in The Netherlands,
including Endocan B.V., for the Company's expanding European
operations.
About Endocan Corporation
The brand name Endocan™ was chosen by the Board as a direct
reference to the endocannabinoid system of the human body. The
endocannabinoid system is a group of neuromodulatory compounds and
their receptors that are involved in a variety of fundamental
physiological processes including pain-sensation, immune function,
stress, sleep, mood, appetite, and memory. Cannabinoids from
plants, including those found in the Cannabis genus, as well as
those autonomously produced within living biological systems, work
together in the operation of the endocannabinoid system. The
modulation of this system is the basis for cannabinoid-based
medical treatments to assist patients to improve their health and
well-being.
Endocan Corporation, (FKA The X-Change Corporation) is currently
developing new natural cannabinoid containing products based on
innovative formulations to utilize the unique and potent benefits
of the cannabis and hemp plants. Medicinal properties of cannabis
and hemp have been known and applied for thousands of years. With
the aid of scientific research, Endocan Corporation is translating
such knowledge into development of effective cannabinoid
formulation-based health and wellness solutions as well as
cosmeceutical, nutraceutical, and food brands throughout the world.
The Company's health and wellness, nutritional, and cosmetics lines
will address personal needs and will evolve with the introduction
of new formulations and products, advancing the Company within the
expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. The Company does not undertake any duty nor does it intend
to update the results of these forward-looking statements.
Endocan Corporation
President & CEO
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO & SVP Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation